The interview explores the complex disease pathway of prostate cancer, focusing on patient segmentation and relapse rates. It discusses the rationale behind standard-of-care treatment options across different disease states, highlighting how clinical factors—such as mutational status, disease burden, and PSA doubling time—influence treatment selection.

This interview was conducted on Feb 10, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.